Zavesca (Miglustat) is a glucosylceramide synthase inhibitor. It is used treat mild-to-moderate cases of a rare genetic disease known as type I Gaucher disease, where there is a buildup of glucosylceramide in the body's immune system.
Available form
Capsule
Dosage
Manufacturer
Janssen
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
For type I Gaucher disease, the recommended adult dose is 100 mg taken by mouth, 3 times daily at regular intervals.
For Niemann-Pick type C disease, the recommended dose for people over 12 years of age is 200 mg taken by mouth 3 times daily. The children's dose is based on body weight.
Zavesca (Miglustat) should be swallowed whole with a glass of water. It may be taken with or without food.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
It is important to take Zavesca (Miglustat) exactly as prescribed by your doctor. If you miss a dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are not sure what to do after missing a dose, contact your doctor or pharmacist for advice.
Store Zavesca (Miglustat) at room temperature, protect it from moisture, and keep it out of the reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent. The side effects listed below are not experienced by everyone who takes Zavesca (Miglustat). If you are concerned about side effects, discuss the risks and benefits of Zavesca (Miglustat) with your doctor.
The following side effects have been reported by at least 1% of people taking Zavesca (Miglustat). Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of the side effects listed below don't happen very often, they could lead to serious problems if you do not check with your doctor or seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Zavesca (Miglustat).
Each white opaque capsule, with "OGT 918" in black on the cap and "100" in black on the body of the capsule, contains Zavesca (Miglustat) 100 mg. Nonmedicinal ingredients: magnesium stearate, povidone (K30), sodium starch glycollate, gelatin, titanium dioxide (E171), water, black iron oxide (E172), potassium hydroxide, propylene glycol, and shellac.
Zavesca (Miglustat) should not be taken by anyone who:
Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications that you are taking. Also tell them about any supplements you take. Since caffeine, alcohol, the Nicotine from cigarettes, or street drugs can affect the action of many medications, you should let your prescriber know if you use them. Depending on your specific circumstances, your doctor may want you to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use Zavesca (Miglustat).
Bleeding: Zavesca (Miglustat) may cause a reduced number of platelets in the blood, which can make it difficult to stop cuts from bleeding. If you notice any signs of bleeding, such as frequent nosebleeds, unexplained bruising, or black and tarry stools, notify your doctor as soon as possible.
Diarrhea: Diarrhea is a very common side effect of Zavesca (Miglustat). If you experience diarrhea, taking Zavesca (Miglustat) between meals may help. If the diarrhea is bothersome, contact your doctor.
Dizziness/reduced alertness: Zavesca (Miglustat) commonly causes dizziness. Avoid driving or operating machinery until you know how Zavesca (Miglustat) affects you.
Kidney Disease: Zavesca (Miglustat) is removed from the body by the kidneys and its elimination may be reduced in people with kidney disease. If you have kidney disease, discuss with your doctor how Zavesca (Miglustat) may affect your medical condition, how your medical condition may affect the dosing and effectiveness of Zavesca (Miglustat), and whether any special monitoring is needed.
Severe Gaucher disease: The safety and effectiveness of Zavesca (Miglustat) have not been evaluated for people with severe Gaucher disease. Zavesca (Miglustat) is used for mild-to-moderate type 1 Gaucher disease.
Pregnancy: Zavesca (Miglustat) should not be used by women during pregnancy as it may cause harm to the unborn baby. Both men and women should use a reliable method of contraception. Men should not father a child while they are taking Zavesca (Miglustat) and for 3 months after stopping the medication. If you become pregnant while you are taking Zavesca (Miglustat), contact your doctor immediately.
Breast-feeding: It is not known if Zavesca (Miglustat) passes into breast milk. If you are a breast-feeding mother and are taking Zavesca (Miglustat), it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
Children: The safety and effectiveness of using Zavesca (Miglustat) for type I Gaucher disease have not been established for children under 18 years of age. The safety and effectiveness of using Zavesca (Miglustat) for Niemann-Pick type C disease have not been established for children under 4 years of age.
price lookup
Total no. of dose(s)
Manufacturer
Insurance coverage
Dosage
*Actual pricing may differ. Medication is only available by prescription. The cost may be subsidised by your provincial or private health plan.
price details
Total (CAD)
--*
Drug info not available
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer